Home About us Editorial board Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 355
  • Home
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2022  |  Volume : 29  |  Issue : 2  |  Page : 89-95

Adverse Events Following COVID-19 Vaccination in Rivers State, Nigeria: A Cross-Sectional Study


1 Department of Community Medicine, College of Medical Sciences, Rivers State University; Rivers State Primary Health Care Management Board, Port Harcourt, Nigeria
2 Rivers State Primary Health Care Management Board, Port Harcourt, Nigeria

Correspondence Address:
Clement Kevin Edet
Rivers State Primary Healthcare Management Board, Port Harcourt
Nigeria
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/npmj.npmj_11_22

Rights and Permissions

Context: Coronavirus disease (COVID-19) has led to over 2,589,638 deaths globally as of March 2021 and speedy discovery of vaccines. Nigeria started the phase one COVID-19 vaccination in March 2021 using the Oxford AstraZeneca vaccine. Reports of severe adverse events with the Oxford AstraZeneca vaccine resulted in its suspension in some countries necessitating the need to determine its safety. Aims: To assess the prevalence, types and severity of the adverse events following COVID-19 vaccination in Rivers State, Nigeria. Settings and Design: A cross-sectional study design was adopted. Subjects and Methods: Simple random sampling method was used to select a total of 428 adults from recipients of the first dose of COVID-19 vaccine within 28 days of vaccination. A questionnaire adapted from World Health Organisation was interviewer-administered through phone calls; responses were recorded on Kobo Toolbox. Statistical Analysis Used: Descriptive analysis of variables was done and the association between adverse events and age, allergy and medical history were determined. The level of statistical significance was predetermined at a P < 0.05. Results: In this study, 50.5% of respondents reported post-vaccination adverse events out of which 10 (4.6%) were severe (30% of the severe cases were life-threatening, 60% were hospitalised and 10% were placed on bed rest). The most common side effects were fever (73.0%), pain at the injection site (41.2%), fatigue (33.3%), body ache (17.5%) and headache (13.8%). No significant association was observed between the incidence of severe adverse events and participants with allergies or medical history. Conclusions: The adverse events associated with the COVID-19 vaccine were largely mild and resolved within a few days. Further research is required to classify adverse events into categories.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1647    
    Printed52    
    Emailed0    
    PDF Downloaded170    
    Comments [Add]    

Recommend this journal